2025-10-03 - Analysis Report
Okay, here's an analysis of Colgate-Palmolive (CL) based on the provided data.

## Colgate-Palmolive (CL) Stock Analysis

**Company Overview:** Colgate-Palmolive Co. is a global consumer products company specializing in the production, distribution, and marketing of household, health care, personal care, and pet nutrition products.

### 1. Performance vs. S&P 500 (VOO)

*   **CL Ticker:** CL
*   **CL Cumulative Return:** 0.96%
*   **VOO Cumulative Return:** 97.56%
*   **Deviation:**
    *   Maximum: 8.7
    *   Minimum: -98.2
    *   Current: -96.6
    *   Relative Deviation: 1.5

**Analysis:** CL has significantly underperformed the S&P 500 (VOO) over the period analyzed. The current deviation is near the minimum observed, indicating substantial underperformance. The Relative Deviation of 1.5 suggests that the underperformance is towards the lower end of its historical range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------- | ----- | ------ |
| 2015-2017  | 13.0%  | 4.2%   | -16.0%  | 0.1   | 61.0   |
| 2016-2018  | -12.0% | 72.1%  | -28.0%  | 0.0   | 48.1   |
| 2017-2019  | 0.0%   | 72.1%  | -22.0%  | -0.3  | 55.6   |
| 2018-2020  | 3.0%   | 81.3%  | -21.0%  | 0.2   | 69.1   |
| 2019-2021  | 18.0%  | 81.3%  | -29.0%  | 1.2   | 69.0   |
| 2020-2022  | 4.0%   | 81.3%  | 5.0%    | 1.9   | 63.7   |
| 2021-2023  | 6.0%   | 80.0%  | 5.0%    | 0.3   | 64.4   |
| 2022-2024  | 21.0%  | 80.0%  | 1.0%    | 0.2   | 73.5   |
| 2023-2025  | -3.0%  | 76.6%  | -65.0%  | 0.5   | 64.6   |

**Analysis:**
*   **CAGR:** Fluctuating CAGR indicating inconsistent growth.
*   **MDD:** High Maximum Drawdown values suggesting significant risk in some periods.
*   **Alpha:** Predominantly negative Alpha values suggest underperformance relative to a benchmark.
*   **Beta:** Low Beta values indicate low volatility compared to the market.
*   **Cap(B):** Relatively stable market capitalization around $60-70 billion.

### 2. Recent Stock Price Movement

*   **Current Price:** 79.9
*   **Last Market Data:**
    *   Price: 78.31
    *   Previous Close: 79.01
    *   Change: -0.89
*   **Moving Averages:**
    *   5-day: 80.29
    *   20-day: 82.22
    *   60-day: 85.03

**Analysis:** The stock price is below all three moving averages, indicating a short-term downtrend. The recent price change of -0.89 suggests a slight decline and should be noted, the difference between `price` and `previousClose` shows a small downtrend issue.

### 3. Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 31.41 (Approaching Oversold)
*   **PPO:** -0.2284
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (12 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Deviation Change:** 1.5 (+): Short-term Increase
*   **Expected Return (%):** -2232.7

**Analysis:**

*   The high MRI suggests that, despite the current market conditions, CL is considered relatively safe.
*   The RSI is approaching oversold territory, which could indicate a potential buying opportunity.
*   The Hybrid Signal suggests a strong buy signal, indicating potential optimism in current conditions
*   The positive change in relative deviation indicates a short-term increase.
*   The significantly negative Expected Return is a major red flag, suggesting potential issues in long-term investment.

### 4. Recent News & Significant Events

*   **Market Outlook:** Reports on the European household care market include Colgate-Palmolive.
*   **Analyst Ratings:** BNP Paribas Exane adjusted the price target to $91 with an Outperform rating. Rothschild & Co Redburn adjusted the price target to $84 with a Neutral rating. Goldman Sachs adjusted the price target to $91 with a Buy rating.
*   **Dividend:** Colgate-Palmolive is highlighted as a steady dividend payer in the S&P 500.

**Analysis:** Analyst opinions are mixed, with price target adjustments and varied ratings. The steady dividend payout is a positive factor for income-focused investors.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 2.05)
*   **Target Price:** Avg: $93.61 / High: $105.00 / Low: $82.00

**Analysis:** The analyst consensus leans towards a "Buy" rating, with a target price significantly higher than the current price, suggesting potential upside.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출     |
| ---------- | ---- | -------- |
| 2025-08-01 | 0.92 | 5.11 B$  |
| 2025-04-25 | 0.85 | 4.91 B$  |
| 2024-10-25 | 0.9  | 5.03 B$  |
| 2024-07-26 | 0.89 | 5.06 B$  |
| 2025-08-01 | 0.89 | 5.06 B$  |

**Analysis:** EPS and revenue have been relatively stable over the past few quarters. The latest EPS shows a slight increase.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-06-30 | $5.11B  | 60.06%        |
| 2025-03-31 | $4.91B  | 60.82%        |
| 2024-12-31 | $4.95B  | 60.30%        |
| 2024-09-30 | $5.03B  | 61.08%        |
| 2024-06-30 | $5.06B  | 60.62%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
| ---------- | ------- | --------- |
| 2025-06-30 | $0.70B | 105.84%   |
| 2025-03-31 | $0.36B | 190.08%   |
| 2024-12-31 | $0.21B | 348.58%   |
| 2024-09-30 | $0.43B | 169.43%   |
| 2024-06-30 | $0.12B | 594.31%   |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue is consistent, and the profit margin remains high, indicating strong operational efficiency.
*   **Capital and Profitability:** Equity values are relatively low, while the ROE is extremely high. This combination may warrant further investigation to understand the company's capital structure and financial leverage. The increasing ROE over time may indicate better profitability in relation to equity.

### 7. 종합 Analysis

**Summary:**

Colgate-Palmolive (CL) presents a mixed outlook. While the company demonstrates stable revenue and high-profit margins, it has significantly underperformed the S&P 500. Recent stock price movements show a downtrend. The high MRI and approaching oversold RSI could signal a potential buying opportunity, but the significantly negative Expected Return is concerning.

**Key Takeaways:**

*   **Underperformance:** CL has significantly underperformed the S&P 500, indicating potential issues with growth or market perception.
*   **Analyst Opinion:** Analyst ratings are mixed, with price targets suggesting potential upside but varied recommendations.
*   **Financial Stability:** Strong revenue, profit margins, and steady dividend payouts indicate financial stability.
*   **Risk Factors:** Extremely negative Expected Returns should be considered, requiring investors to be cautious about long-term accumulation strategies. The combination of low equity and extremely high ROE may indicate high financial leverage or other balance sheet characteristics that warrant deeper investigation.
*   **Short-Term vs. Long-Term:** Short-term indicators may suggest a potential buying opportunity, but long-term prospects, particularly based on the Expected Return, raise concerns.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. Further research is needed to understand the reasons behind the significant underperformance and negative Expected Return. While the high MRI suggests relative safety, the negative Expected Return indicates potential issues with long-term accumulation strategies, highlighting the need for careful consideration and due diligence before making any investment decisions.
